https://www.PR.com/ Latest news releases from PR.com for Pharmaceuticals. Mon, 13 Jul 2026 20:56:36 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/973172 Thu, 09 Jul 2026 03:00:00 -0400 Validation Management Solutions (VMS) has appointed Remoun Amin as Partner, marking an important milestone in the company's growth. With more than two decades of life sciences experience, Amin strengthens VMS's ability to deliver expert CQV, calibration, and temperature mapping services while advancing its vision to help clients build assurance that scales with them. [PR.com] https://www.pr.com/press-release/973172 Validation Managment Solutions https://www.pr.com/press-release/971739 Mon, 22 Jun 2026 08:00:00 -0400 Announced at the Cannes Lions Festival, the collaboration pairs senior communications expertise with innovative scientific storytelling. [PR.com] https://www.pr.com/press-release/971739 GW Health Agency https://www.pr.com/press-release/970630 Tue, 09 Jun 2026 09:00:00 -0400 DSV launches the latest expansion of its Air ThermoDirect solution through Indianapolis International Airport, strategically strengthening pharmaceutical supply chains with enhanced cold-chain connectivity from one of the United States’ fastest-growing life sciences and healthcare logistics hubs. By minimizing time spent in uncontrolled environments and removing the complexity of active containers, Air ThermoDirect [PR.com] https://www.pr.com/press-release/970630 DSV https://www.pr.com/press-release/970102 Thu, 04 Jun 2026 03:00:00 -0400 Alera Bio announced the appointment of David McCullough as Chief Executive Officer. An experienced biotechnology executive, McCullough will lead corporate strategy, financing, organizational development, and execution of the company’s clinical and regulatory roadmap. He will oversee advancement of AB-101, Alera’s novel therapy for MCT-8 deficiency, as the company works to bring new hope to patients and families [PR.com] https://www.pr.com/press-release/970102 Alera Bio https://www.pr.com/press-release/969506 Wed, 27 May 2026 08:04:56 -0400 SPARK Industries announced advancements in its patent-pending MRI signal-analysis platform designed to detect previously unresolved neurological and structural signatures within raw MRI data. Internal validation across 1,000+ clinical MRI cases involving TBI, Alzheimer’s, Parkinson’s, and prostate cancer demonstrated consistent signal relationships associated with known disease states. SPARK is now pursuing blinded [PR.com] https://www.pr.com/press-release/969506 SPARK Industries Corporation https://www.pr.com/press-release/968130 Thu, 14 May 2026 17:29:14 -0400 Category creating solution gives community and advanced practice pharmacists the clinical workflow, EHR integration, and billing infrastructure needed to fully exercise their prescriptive authority — closing the gap between legal authority and real-world practice. [PR.com] https://www.pr.com/press-release/968130 HourScript https://www.pr.com/press-release/967244 Thu, 14 May 2026 14:11:01 -0400 Mediprocity is excited to announce a partnership with SuiteRx. Mediprocity’s secure messaging tool is now available through a seamless integration into SuiteRx pharmacy management software. The integration promises robust, instant, HIPAA-secure collaboration that streamlines workflows for pharmacies and the facilities and providers they service. Using slow, outdated technology in LTC - leaving voicemails, waiting [PR.com] https://www.pr.com/press-release/967244 Mediprocity https://www.pr.com/press-release/967144 Mon, 04 May 2026 18:04:17 -0400 Central Indiana is now home to the largest pharma-grade 2°–8°C cooler environment in the United States. [PR.com] https://www.pr.com/press-release/967144 Langham Logistics https://www.pr.com/press-release/967252 Thu, 30 Apr 2026 16:38:00 -0400 PVT401, a peptide-MHC nanomedicine, is the second Parvus drug candidate to enter clinical trials. [PR.com] https://www.pr.com/press-release/967252 Parvus Therapeutics U.S., Inc. https://www.pr.com/press-release/966715 Tue, 28 Apr 2026 11:50:48 -0400 PHARMCHINA 2026 (May 13–15, Shanghai) brings 2,000+ exhibitors together as a key gateway to China’s fast‑growing FDF market, offering global pharma firms critical sourcing, partnering, and regulatory insights before mid‑year decisions close. [PR.com] https://www.pr.com/press-release/966715 RX https://www.pr.com/press-release/966266 Tue, 21 Apr 2026 03:00:00 -0400 Unified company introduces evolved identity and expanded capabilities to help providers and suppliers make fair, fact-based decisions. [PR.com] https://www.pr.com/press-release/966266 Curvo https://www.pr.com/press-release/965788 Tue, 14 Apr 2026 15:47:27 -0400 New Division of NEMA Focused on Strengthening Personalized Care for Patients [PR.com] https://www.pr.com/press-release/965788 Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA) https://www.pr.com/press-release/965253 Thu, 09 Apr 2026 03:00:00 -0400 Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. [PR.com] https://www.pr.com/press-release/965253 Alera Bio https://www.pr.com/press-release/964115 Tue, 31 Mar 2026 09:00:00 -0400 PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. [PR.com] https://www.pr.com/press-release/964115 ALS Therapy Development Institute https://www.pr.com/press-release/964221 Tue, 31 Mar 2026 11:59:00 -0400 Regller LLC, an AI-driven quality maturity SaaS platform for FDA-regulated industries, today announced the appointment of Kamal Biswas as its Chief Executive Officer. Kamal co-founded Regller and previously served on its board. With over 25 years of leadership experience across life sciences and technology, he brings deep expertise in pharmaceutical manufacturing, quality and compliance, management consulting to major [PR.com] https://www.pr.com/press-release/964221 Regller https://www.pr.com/press-release/964328 Fri, 27 Mar 2026 03:00:00 -0400 SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide inhibitor for the treatment of retinopathy of prematurity (ROP). “Orphan Drug Designation for ROP represents a significant [PR.com] https://www.pr.com/press-release/964328 SignaBlok, Inc. https://www.pr.com/press-release/962938 Fri, 27 Mar 2026 09:42:00 -0400 The Web Marketing Association has opened entries for the 30th Annual WebAward Competition, inviting hospitals, medical practices, and healthcare organizations worldwide to compete for recognition as the best medical websites of 2026. Websites will be evaluated on design, innovation, usability, and technology. Winners gain industry recognition and valuable benchmarking insights. Entry deadline: May 29, 2026. [PR.com] https://www.pr.com/press-release/962938 Web Marketing Association https://www.pr.com/press-release/964330 Thu, 26 Mar 2026 14:34:07 -0400 • In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy [PR.com] https://www.pr.com/press-release/964330 SignaBlok, Inc. https://www.pr.com/press-release/960352 Sat, 28 Feb 2026 09:02:07 -0500 Komal Medical & Provision Store is a familiar and trusted name in Jaipur. The store has a strong presence in the city, not for now, but for many years. It is known for its reliable service and genuine medicine, with an aim for maximum client satisfaction. Daily, hundreds of people buy prescription medicines, wellness products, and other pharmacy products. Komal Medical & Provision Store built its reputation on [PR.com] https://www.pr.com/press-release/960352 Direct Dawai https://www.pr.com/press-release/960593 Fri, 13 Feb 2026 03:00:00 -0500 Thar has a 35-year history of building automated supercritical systems and operating R&D labs. For many years, Thar also built CO2 delivery systems to make it easier for any client to access CO2 without the inconvenience of CO2 bottles/tanks inside the lab. This automation provides a fast return on investment for company's trying to mitigate labor costs and safety risks. [PR.com] https://www.pr.com/press-release/960593 Thar Process https://www.pr.com/press-release/959756 Wed, 04 Feb 2026 03:00:00 -0500 Bio-Neuroscience today announced the selection of 12 neuroscience drug development companies to present at Bio-Neuroscience 2026, the premier global gathering of neuroscience innovation leaders, investors, and pharmaceutical executives. The companies were chosen from a competitive international field following rigorous evaluation of their scientific innovation, clinical progress, therapeutic approach, and commercial [PR.com] https://www.pr.com/press-release/959756 Broadreach Global LLC https://www.pr.com/press-release/958774 Thu, 29 Jan 2026 09:48:29 -0500 In 2026, I Holland proudly reaches an exciting milestone: 80 years of excellence in tablet compression tooling. Founded in 1946, I Holland has spent eight decades advancing tablet compression technology, sharing industry-leading expertise, and supporting customers around the world. To celebrate this anniversary, I Holland is delighted to announce a worldwide series of free technical seminars, taking place throughout [PR.com] https://www.pr.com/press-release/958774 I Holland Ltd. https://www.pr.com/press-release/958035 Wed, 14 Jan 2026 03:00:00 -0500 INTERPHEX WEEK TOKYO, Japan’s largest pharmaceutical and biotech show, will take place from May 20 to 22, 2026, at Makuhari Messe, bringing together a comprehensive range of products and services related to pharmaceuticals and regenerative medicine, and is expected to attract approximately 35,000 visitors and feature around 950 exhibitors. With six specialized exhibitions under one roof, INTERPHEX WEEK TOKYO [PR.com] https://www.pr.com/press-release/958035 RX https://www.pr.com/press-release/957850 Tue, 13 Jan 2026 20:45:00 -0500 CanVeer announces the launch of the validation program for its flagship product, AlveoShield™ (Investigational New Drug). The program targets preterm newborns with or at risk of developing bronchopulmonary dysplasia (BPD). Bronchopulmonary dysplasia is a chronic respiratory disease affecting preterm neonates who require assisted ventilation. AlveoShield™ is designed to potentially prevent and treat BPD. CanVeer also [PR.com] https://www.pr.com/press-release/957850 CanVeer Biopharma Inc. https://www.pr.com/press-release/957853 Thu, 08 Jan 2026 16:30:00 -0500 Pharmacy XD LLC, a fully licensed Florida Department of Health–approved national mail order pharmacy and distribution facility, today officially announces its direct-to-patient (DTP) platform. Positioned in the heart of one of Florida’s most dynamic healthcare and life sciences regions, Pharmacy XD is strategically located just minutes from Moffitt Cancer Center’s Speros, FL campus - a 775-acre [PR.com] https://www.pr.com/press-release/957853 Pharmacy XD LLC https://www.pr.com/press-release/956688 Tue, 30 Dec 2025 15:43:23 -0500 Cumberland Biotherapeutics, LLC, a dental innovation company integrating advanced bioactive glass with botanicals, today announced the U.S. launch of DentoClude F; DentoClude F is marketed under a commercial name for the Occlude® F Dentin Tubule Agent, which received FDA 510(k) clearance under K082071. DentoClude F will be distributed exclusively through licensed dental professionals in the United States, expanding [PR.com] https://www.pr.com/press-release/956688 Cumberland Biotherapeutics, Inc https://www.pr.com/press-release/957046 Mon, 29 Dec 2025 08:38:07 -0500 Biostem Pharma Private Limited strengthens its position as a preferred partner for third-party pharma manufacturing in India. The company offers WHO-GMP-compliant production of tablets, capsules, syrups, and topical formulations, catering to both startups and established pharma brands. [PR.com] https://www.pr.com/press-release/957046 Biostem Pharma Pvt Ltd https://www.pr.com/press-release/956998 Sat, 27 Dec 2025 06:39:55 -0500 Curasia Medilabs Private Limited announces monopoly-based PCD pharma franchise opportunities, offering exclusive territories, a diversified product range, and structured partner support across India. [PR.com] https://www.pr.com/press-release/956998 Curasia Medilabs Pvt. Ltd. https://www.pr.com/press-release/956777 Wed, 24 Dec 2025 03:00:00 -0500 Orange Biotech has launched an advanced Third-Party Pharma Manufacturing platform aimed at helping pharma companies, startups, and PCD franchise owners manufacture high-quality formulations efficiently. The platform offers WHO-GMP compliant production, customized product development, regulatory assistance, and pan-India distribution support, strengthening Orange Biotech’s position as a trusted B2B pharma solutions [PR.com] https://www.pr.com/press-release/956777 Orange Biotech Pvt. Ltd. https://www.pr.com/press-release/955738 Thu, 11 Dec 2025 03:00:00 -0500 INTERPHEX WEEK TOKYO, Asia’s leading comprehensive exhibition for the pharmaceutical and biotech industry, will return to Makuhari Messe on May 20–22, 2026, with exhibitor applications now open, offering an exceptional opportunity for companies to showcase their innovations and connect with thousands of industry professionals from Japan and across Asia. Recognised as Japan’s largest research and [PR.com] https://www.pr.com/press-release/955738 RX https://www.pr.com/press-release/949767 Fri, 05 Dec 2025 10:56:14 -0500 Texas Functional Health Centers has completed the “Importance of Primitive Movements” Seminar, further expanding our knowledge to better serve patients. This training focused on the foundational movement patterns that influence long-term function and recovery. By bringing these insights into our TRUForm rehabilitation system, we’re equipping patients to heal more effectively and move the way their bodies were [PR.com] https://www.pr.com/press-release/949767 Texas Functional Health Centers https://www.pr.com/press-release/953495 Wed, 12 Nov 2025 09:52:00 -0500 PVT201 demonstrated favorable safety, predictable pharmacokinetics, and on-target pharmacodynamic activity in first-in-human study. [PR.com] https://www.pr.com/press-release/953495 Parvus Therapeutics U.S., Inc. https://www.pr.com/press-release/951923 Tue, 28 Oct 2025 20:39:00 -0400 True Marker Pharmaceuticals, Inc., a licensed pharmaceutical wholesaler and repackager based in Phoenix, has earned BBB Accreditation, recognizing its commitment to ethical business practices, transparency, and regulatory compliance. The achievement aligns with True Marker’s expanding U.S. distribution network and reinforces its reputation as a trusted, DSCSA-compliant partner to independent pharmacies and healthcare [PR.com] https://www.pr.com/press-release/951923 True Marker Pharmaceuticals, Inc. https://www.pr.com/press-release/951167 Thu, 16 Oct 2025 09:00:00 -0400 Life Science Strategy Group’s Preclinical Services Landscape and CRO Benchmarking Assessment Delivers Data-Driven Insights on Budgets, Outsourcing, Vendor Preferences, and Industry Shifts [PR.com] https://www.pr.com/press-release/951167 Life Science Strategy Group, LLC https://www.pr.com/press-release/950564 Fri, 10 Oct 2025 09:00:00 -0400 Iridium CE, in partnership with Global Education Group, has won a Silver w3 Award for its AI-powered UTI education program, Rethinking Uncomplicated UTIs. The interactive simulation enables HCPs to diagnose and treat virtual patients in real-time, improving competence, confidence, and antibiotic stewardship. With 1,500+ learners reached and strong outcomes, this marks the program’s second major award. Supported by an [PR.com] https://www.pr.com/press-release/950564 Iridium CE https://www.pr.com/press-release/946412 Tue, 30 Sep 2025 13:08:08 -0400 Aquaterra Biotech Launches Integrated Microbial CDMO Platform from DNA Design to GMP Release Aquaterra Biotech announced an integrated contract development and manufacturing (CDMO) platform that advances microbial and recombinant programs from DNA design to GMP release and logistics. Headquartered in Québec, the science-driven CDMO unifies development and manufacturing to reduce hand-offs, compress timelines, and [PR.com] https://www.pr.com/press-release/946412 Aquaterra Biotech https://www.pr.com/press-release/949746 Mon, 29 Sep 2025 14:34:00 -0400 The FOXG1 Research Foundation announced the FDA has granted Orphan Drug and Rare Pediatric Disease designations to FRF-001, its gene therapy for FOXG1 syndrome. FRF-001 marks a historic first: a parent-led foundation sponsoring its own international, multi-site clinical trial. [PR.com] https://www.pr.com/press-release/949746 FOXG1 Research Foundation https://www.pr.com/press-release/948342 Wed, 17 Sep 2025 10:00:00 -0400 BioSensics has received a 5-year/$5.2 million grant from the National Institutes of Health (NIH) to develop and validate novel digital biomarkers of disease activity in progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB). This 5-year project will leverage BioSensics’ expertise in wearable sensors and digital health technologies and involve close collaboration with leading CurePSP Centers of Care and [PR.com] https://www.pr.com/press-release/948342 BioSensics LLC https://www.pr.com/press-release/947753 Wed, 10 Sep 2025 07:51:06 -0400 Lyfe RX, formerly Live Well RX, announces its official rebrand and launch, introducing a fresh identity and expanded wellness offerings. With personalized weight management, peptide therapies, doctor-curated supplements, and high-protein meal prep, Lyfe RX delivers comprehensive, science-backed solutions to help customers achieve their health, longevity, and wellness goals. [PR.com] https://www.pr.com/press-release/947753 The Lyfe RX https://www.pr.com/press-release/946321 Wed, 27 Aug 2025 11:08:42 -0400 BrainWorks Behavioral Health has expanded into Los Angeles and Orange Counties with new offices in Los Angeles, Whittier, and Irvine. The clinics provide autism testing, ADHD evaluations, therapy, and counseling for children, teens, and adults. For over a decade, BrainWorks has delivered compassionate care across Southern California, now bringing necessary psychological and neuropsychological services to more families. [PR.com] https://www.pr.com/press-release/946321 BrainWorks Behavioral Health https://www.pr.com/press-release/944992 Wed, 06 Aug 2025 18:42:36 -0400 Aptitude Health today announced the acquisition of Hug Advertising, a UK-based creative agency renowned for its expertise in branding, animation, and advertising. [PR.com] https://www.pr.com/press-release/944992 Aptitude Health https://www.pr.com/press-release/944348 Thu, 31 Jul 2025 09:20:48 -0400 Apelo Consulting has released a report on Global Multiple Myeloma Therapeutics Market (By Disease, Treatment, Route of Administration, End User, Regional Analysis), Company Profiles, Market Dynamics and Recent Developments – Forecast to 2030. [PR.com] https://www.pr.com/press-release/944348 Apelo Consulting Pvt. Ltd. https://www.pr.com/press-release/943624 Tue, 22 Jul 2025 09:16:41 -0400 GENINVO, a leading provider of transformative digital solutions for the life sciences sector, proudly celebrates its 8th anniversary—a journey marked by innovation, collaboration, and impactful contributions across global healthcare and pharmaceutical domains. From a vision sparked eight years ago to bring smarter, cutting-edge development to life sciences, GENINVO has evolved into a trusted partner for sponsors [PR.com] https://www.pr.com/press-release/943624 GenInvo, Inc. https://www.pr.com/press-release/942777 Tue, 22 Jul 2025 06:44:39 -0400 Medspartner supports UK cancer and rare disease patients in accessing affordable medications through legal personal importation when NHS options are unavailable or costly. [PR.com] https://www.pr.com/press-release/942777 Medspartner https://www.pr.com/press-release/942957 Fri, 18 Jul 2025 13:58:51 -0400 The ALS Network, a mission-driven organization committed to advancing treatments and improving quality of life for people living with amyotrophic lateral sclerosis (ALS), has launched its first AI-based clinical trial finder—powered by TrialX—to help individuals and families affected by ALS access personalized, up-to-date information about clinical trials. [PR.com] https://www.pr.com/press-release/942957 TrialX https://www.pr.com/press-release/942814 Thu, 10 Jul 2025 03:00:00 -0400 Aphora Health, a leading provider of cost containment solutions and advanced pharmacy benefit strategies for self-insured employers, announces the acquisition of CareNexis, a digital health company known for its proprietary consumer health intelligence and engagement platform. This acquisition represents a strategic step in Aphora Health’s mission to modernize how self-insured employers manage rising prescription [PR.com] https://www.pr.com/press-release/942814 Aphora Health https://www.pr.com/press-release/942290 Thu, 03 Jul 2025 03:00:00 -0400 Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. [PR.com] https://www.pr.com/press-release/942290 Alera Bio https://www.pr.com/press-release/941659 Tue, 24 Jun 2025 12:37:52 -0400 The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. [PR.com] https://www.pr.com/press-release/941659 ALS Therapy Development Institute https://www.pr.com/press-release/939937 Tue, 03 Jun 2025 09:14:12 -0400 Fibroblast growth factor technology constitutes a significant breakthrough in the treatment of metabolic and cancer-related diseases. [PR.com] https://www.pr.com/press-release/939937 Anzor Pharmaceuticals https://www.pr.com/press-release/937391 Wed, 30 Apr 2025 18:38:12 -0400 Vetirus Pharmaceuticals, a multinational company headquartered in Naples, Florida, and London, UK, announced its acquisition of Enso Discoveries, LLC, a Manhattan, Kansas-based biotech company specializing in regenerative medicine. The acquisition was revealed at the 10th annual Animal Health, Nutrition, and Technology Innovation Europe. [PR.com] https://www.pr.com/press-release/937391 Vetirus Animal Health https://www.pr.com/press-release/937132 Sat, 26 Apr 2025 03:00:00 -0400 Pennington Biomedical researchers included Dr. Eric Ravussin, Dr. Corby Martin, Dr. Robbie Beyl, Dr. Frank Greenway, and Dr. Guillermo Sanchez-Delgado. [PR.com] https://www.pr.com/press-release/937132 Pennington Biomedical Research Center https://www.pr.com/press-release/935983 Sat, 12 Apr 2025 03:00:00 -0400 GENINVO, a leading provider of life science technology solutions, is proud to announce the launch of its latest innovation – the Confidential Information Scanner (CIS) Tool. This tool is designed to help organizations identify publicly available company confidential information (CCI) across multiple sources. The pharmaceutical and life sciences industries handle large volumes of sensitive data, making data [PR.com] https://www.pr.com/press-release/935983 GenInvo, Inc. https://www.pr.com/press-release/935084 Tue, 01 Apr 2025 10:27:39 -0400 Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation from DCI Partners, Taya Venture Capital, KDI Marketing, Huahai US, Hercules BioVenture LP, and TTM 2025 LLC. We are thrilled [PR.com] https://www.pr.com/press-release/935084 Apeximmune Therapeutics https://www.pr.com/press-release/934966 Sun, 30 Mar 2025 03:00:00 -0400 This integration provides OpenEMR users the ability to electronically transmit prescriptions securely and efficiently—without the need for traditional third-party networks. [PR.com] https://www.pr.com/press-release/934966 Weno Exchange LLC https://www.pr.com/press-release/934383 Mon, 24 Mar 2025 09:18:00 -0400 Thar Process and Clean Heat Technologies have successfully engineered, integrated and installed electric heat pumps using CO2 - R744 - as the upcycled, natural refrigerant. The technology partnership means that Thar Process' clients can benefit from lower operating costs. Thar is known for it's innovative use of CO2 for extracting flavors, fragrances, medicinal and therapeutic compounds both in it's GMP certified [PR.com] https://www.pr.com/press-release/934383 Thar Process https://www.pr.com/press-release/933949 Wed, 19 Mar 2025 08:00:00 -0400 BIOPLUS-INTERPHEX KOREA (BIX) 2025 is poised to become the main hub of biopharmaceutical innovation, taking place from October 15-17, 2025, at Coex, Seoul. This event will gather researchers, specialists, and industry leaders from around the globe to explore advancements that are shaping the future of biopharma. BIX 2025 will spotlight four specialized pavilions, each dedicated to a critical area of the pharmaceutical [PR.com] https://www.pr.com/press-release/933949 RX https://www.pr.com/press-release/933872 Tue, 18 Mar 2025 08:07:00 -0400 The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the discoverability, accessibility, and citability of the ALS Research Collaborative (ARC) dataset, a vital resource in the global search for [PR.com] https://www.pr.com/press-release/933872 ALS Therapy Development Institute https://www.pr.com/press-release/933170 Wed, 12 Mar 2025 10:04:00 -0400 The Web Marketing Association is now accepting entries for the 29th annual WebAward Competition, recognizing the best websites of 2025 across 86 industries, including many medical related industries. Judged by industry experts, winners gain valuable feedback, SEO benefits, and global recognition. The entry deadline is May 30, 2025. Don’t miss your chance to showcase your digital excellence—enter today at [PR.com] https://www.pr.com/press-release/933170 Web Marketing Association https://www.pr.com/press-release/932501 Thu, 27 Feb 2025 09:00:00 -0500 How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing [PR.com] https://www.pr.com/press-release/932501 Life Science Strategy Group, LLC https://www.pr.com/press-release/930210 Thu, 06 Feb 2025 07:00:00 -0500 Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, ​a member of the Roche Group​. This strategic acquisition underscores Legacy Pharma's commitment to [PR.com] https://www.pr.com/press-release/930210 Legacy Pharma Inc. SEZC https://www.pr.com/press-release/930156 Wed, 29 Jan 2025 05:37:00 -0500 The Florida Association of ACOs (FLAACOs) announced that GalenusRx, a leader in precision medication safety analytics and polypharmacy risk management, has joined its network as a business partner. This partnership will connect GalenusRx with ACOs across Florida, equipping them with innovative solutions to identify high-risk cohorts of patients, prevent adverse drug events (ADEs), improve outcomes, and reduce total [PR.com] https://www.pr.com/press-release/930156 Florida Association of ACOs https://www.pr.com/press-release/929118 Thu, 16 Jan 2025 03:00:00 -0500 Purple Diamond, a leading ISO-accredited package testing lab, will host a free webinar on February 4, at 2 pm EST. "Protecting Pharma Integrity: The Science of Packaging Validation" will provide insights into testing methodologies and tools critical for ensuring pharmaceutical packaging safety and compliance. [PR.com] https://www.pr.com/press-release/929118 Purple Diamond Testing https://www.pr.com/press-release/928823 Fri, 10 Jan 2025 11:08:00 -0500 Bench International, the longest-serving woman-founded executive search firm in life sciences, is proud to celebrate its 50th Anniversary, marking five decades of shaping transformative leadership in the industry. This milestone will be commemorated at a special gala event next week in San Francisco, during the JP Morgan Healthcare Conference. Bench International invites members of the media to attend this landmark event [PR.com] https://www.pr.com/press-release/928823 Bench International https://www.pr.com/press-release/928559 Tue, 07 Jan 2025 10:08:00 -0500 Conigen Bioscience, Inc., based in Worcester, Massachusetts, has partnered with North Star Scientific, Inc. to expand access to its transformative protein tools across North America. Conigen pioneers innovations in bioactive conformational soluble dimer proteins and membrane proteins displayed on nanoparticles, assay development, and custom protein production services. By integrating advanced protein engineering, [PR.com] https://www.pr.com/press-release/928559 Conigen Bioscience, Inc https://www.pr.com/press-release/927625 Wed, 18 Dec 2024 18:49:41 -0500 The recent Madison, WI school shooting brings the usual cries for gun control, when that is not the point. Legally prescribed psych drugs are making kids crazy and violent. [PR.com] https://www.pr.com/press-release/927625 The Harte of Chiropractic, P.C https://www.pr.com/press-release/926894 Thu, 12 Dec 2024 03:00:00 -0500 Vamstar partners with Nordic consultancy Pricia to combine its AI-driven Pricing Co-Pilot with Pricia’s expertise in pricing strategy, support, and turnkey systems, enhancing pharma pricing decisions. [PR.com] https://www.pr.com/press-release/926894 Vamstar https://www.pr.com/press-release/926698 Sat, 07 Dec 2024 03:00:00 -0500 Today, the Arizona Pharmacy Association (AzPA), the leading voice for Arizona’s pharmacy professionals, announced the appointment of Garet Turner as its new Chief Executive Officer. Turner, a seasoned management, membership and fundraising professional will take the helm on January 6. “Garet has demonstrated a significant amount of leadership in associations and an innovative mindset that we need to stay [PR.com] https://www.pr.com/press-release/926698 Arizona Pharmacy Association https://www.pr.com/press-release/925579 Tue, 19 Nov 2024 12:30:00 -0500 Let’s Win Pancreatic Cancer, a go-to resource that guides patients and caregivers with vital information for better outcomes, launches a new global AI-based clinical trial finder - powered by TrialX - that aims to increase accessibility of clinical trial information for patients and families affected by pancreatic cancer. [PR.com] https://www.pr.com/press-release/925579 TrialX https://www.pr.com/press-release/925344 Thu, 14 Nov 2024 11:11:44 -0500 Nuvem, a high-growth, healthcare technology company offering an integrated suite of pharmacy claims administration, high-level of 340B support and services and onsite pharmacy management services to safety net healthcare providers, announced today that Scott Seidelmann has joined the Company as its new Chief Executive Officer, effective immediately. Seidelmann has more than 25 years of experience in provider-oriented [PR.com] https://www.pr.com/press-release/925344 Nuvem https://www.pr.com/press-release/924860 Sat, 09 Nov 2024 03:00:00 -0500 NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research [PR.com] https://www.pr.com/press-release/924860 NeuroDex https://www.pr.com/press-release/924476 Fri, 08 Nov 2024 08:16:04 -0500 NanoCellect Biomedical, a leading provider of innovative microfluidic flow cytometry solutions, is excited to announce new strategic partnerships with additional distributors in the Asia-Pacific (APAC) region. These partnerships will further expand NanoCellect’s presence in these key markets, enabling scientists to leverage NanoCellect’s proven high-viability cell sorting platforms to advance their research [PR.com] https://www.pr.com/press-release/924476 NanoCellect Biomedical https://www.pr.com/press-release/924421 Mon, 04 Nov 2024 12:25:00 -0500 Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive [PR.com] https://www.pr.com/press-release/924421 SynapsDx https://www.pr.com/press-release/924323 Fri, 01 Nov 2024 08:39:00 -0400 Aptitude Health, a global leader in evidence-based oncology and hematology insights, announces the acquisition of Athena Meetings & Events, a global meetings and events company with over 25 years of experience in the pharmaceutical and healthcare sectors. This strategic acquisition will enable Aptitude Health to strengthen its presence in the UK and European markets and enhance its event management capabilities in [PR.com] https://www.pr.com/press-release/924323 Aptitude Health https://www.pr.com/press-release/924231 Wed, 30 Oct 2024 08:30:00 -0400 Establishing a New Era in Healthcare Communications to Bridge Cultural Gaps and Build Trust [PR.com] https://www.pr.com/press-release/924231 GW Health Agency https://www.pr.com/press-release/924016 Tue, 29 Oct 2024 16:02:35 -0400 Novugen Pharma Sdn. Bhd. proudly announces the successful completion of recent USFDA audit, achieving zero Form 483 citations and No Action Indicated (NAI) status—the highest level of compliance for USFDA-registered manufacturing facilities. This milestone positions Novugen among a select few global companies meeting these standards and reflects the dedication of its team. [PR.com] https://www.pr.com/press-release/924016 Novugen https://www.pr.com/press-release/922199 Mon, 07 Oct 2024 10:49:02 -0400 ClinTrial Research (CTR), proudly welcomes Wendy Tomlinson as the company’s Chief Operating Officer. Tomlinson will oversee activities related to clinical operations, project management, project delivery, and portfolio management. “I am excited for this new chapter and to have the opportunity to work with such a talented team. CTR is implementing a focused and fresh approach to site management,” said [PR.com] https://www.pr.com/press-release/922199 ClinTrial Research https://www.pr.com/press-release/921859 Wed, 02 Oct 2024 16:35:36 -0400 Glucolate Unveils Breakthrough Study from University of California, Irvine: New Powder Form Reduces Glucose Absorption in Type 2 Diabetics Glucolate, an innovative leader in diabetes management, is proud to announce groundbreaking findings from a recent study conducted at the University of California, Irvine. The study highlights the effectiveness of Glucolate’s unique powder formulation, which creates a temporary [PR.com] https://www.pr.com/press-release/921859 Glucolate Processing, LLC https://www.pr.com/press-release/921900 Tue, 01 Oct 2024 18:01:08 -0400 CURE Pharmaceutical, renowned for its innovative sublingual delivery systems, is proud to announce the appointment of Raymond Watt to its Board of Directors. [PR.com] https://www.pr.com/press-release/921900 CURE Pharmaceutical, Inc. https://www.pr.com/press-release/920266 Fri, 13 Sep 2024 11:00:00 -0400 Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances [PR.com] https://www.pr.com/press-release/920266 Quine Biologics, Inc. https://www.pr.com/press-release/919586 Thu, 05 Sep 2024 08:55:00 -0400 The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a crucial need to develop additional therapies and ultimately discover a cure for this devastating genetic disorder. The [PR.com] https://www.pr.com/press-release/919586 Huntington Study Group https://www.pr.com/press-release/919181 Thu, 05 Sep 2024 08:05:00 -0400 Precision Medicine Hero (PMH) announces a preferred partnership with pharmacist-forward precision medicine reporting platform MedTrait®, and pharmacogenetic (PGx) testing laboratory Dynamic DNA Labs, to facilitate their members’ access to advanced solutions for comprehensive PGx-guided medication management. [PR.com] https://www.pr.com/press-release/919181 Precision Medicine Hero https://www.pr.com/press-release/919499 Wed, 04 Sep 2024 07:07:00 -0400 Ember Group Consulting LLC, a new global consulting firm specializing in organizational transformation and adaptive workforce solutions, officially launched today. The firm partners with visionary leaders to drive sustainable change and empower teams for peak performance. Leading Ember Group Consulting is a team of seasoned industry experts: Rochelle Rivas, CEO, and Clint Watson, President. “I'm honored to lead [PR.com] https://www.pr.com/press-release/919499 Ember Group Consulting LLC https://www.pr.com/press-release/919245 Tue, 03 Sep 2024 06:00:00 -0400 Taking place from October 3-5, 2024, in the Boston area, ALS TDI’s Leadership Weekend features a series of community-focused events, including an Open House at ALS TDI’s cutting-edge research lab, the ALS TDI Research Summit, and the White Coat Affair gala. [PR.com] https://www.pr.com/press-release/919245 ALS Therapy Development Institute https://www.pr.com/press-release/918366 Tue, 20 Aug 2024 11:00:00 -0400 The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive Officer, effective September 1, 2024. Dr. Claassen has been involved with the HSG for over 12 years, first as a Site [PR.com] https://www.pr.com/press-release/918366 Huntington Study Group https://www.pr.com/press-release/918232 Fri, 16 Aug 2024 14:52:00 -0400 Chartwell Pennsylvania, LP is proud to announce the launch of a new, nine-chair infusion suite, located in our Oakdale, PA headquarters. CHOICE by Chartwell provides a new alternative for patients to choose where they would like to receive their infusion therapy: at home, or at the new infusion Suite, located just minutes from Robinson Township and Pittsburgh, PA. The suite provides additional options for patients beyond [PR.com] https://www.pr.com/press-release/918232 Chartwell Pennslyvania, LP https://www.pr.com/press-release/917577 Thu, 08 Aug 2024 12:28:38 -0400 Californians fight back against the Board of Pharmacy's proposed regulations that would severely restrict – and in many cases end – access to widely used sterile compounds like methylcobalamin (vitamin B12), glutathione, and NAD, easily accessible and legal in all 49 other United States. The Stop The BOP movement was formed in response, rallying significant public support to preserve access to these essential [PR.com] https://www.pr.com/press-release/917577 Stop The BOP https://www.pr.com/press-release/917390 Tue, 06 Aug 2024 09:58:00 -0400 New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. [PR.com] https://www.pr.com/press-release/917390 Parvus Therapeutics U.S., Inc. https://www.pr.com/press-release/917151 Sat, 03 Aug 2024 03:00:00 -0400 PARIS Technologies International, Inc., developer of a software suite for collaborative FP&A and other performance management solutions, has launched a distributor partnership with Nordica, a highly respected data consulting and analytics firm with business extending throughout Brazil and Latin America. Nordica will focus initially on retail solutions, specifically Retail “Open-to-Buy” strategies to [PR.com] https://www.pr.com/press-release/917151 PARIS Technologies, Inc. https://www.pr.com/press-release/916287 Fri, 02 Aug 2024 11:59:43 -0400 GENINVO has been working towards automating healthcare industry and contributing to faster drug discovery. GENINVO target to bring innovations as technologies, to automate the traditional and time-consuming process of Medical Writing. One example being, automating the process of clinical and regulatory document review. Reviewing clinical and regulatory documents has always been a recurring and time-consuming process. [PR.com] https://www.pr.com/press-release/916287 GenInvo, Inc. https://www.pr.com/press-release/916869 Mon, 29 Jul 2024 15:00:00 -0400 Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human Phase I clinical trial. “Orphan Drug Designation and HREC approval are the latest development milestones which represent [PR.com] https://www.pr.com/press-release/916869 Parvus Therapeutics U.S., Inc. https://www.pr.com/press-release/915936 Tue, 16 Jul 2024 17:00:15 -0400 U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. [PR.com] https://www.pr.com/press-release/915936 microNeb, Inc. https://www.pr.com/press-release/915956 Tue, 16 Jul 2024 16:58:57 -0400 Nuvem, a high-growth, healthcare technology company offering an integrated suite of pharmacy claims administration technology, high-level of 340B support and services and onsite pharmacy management services to safety net healthcare providers, announced that Jim Harter has joined the Company as its new Chief Technology Officer. Mr. Harter brings a wealth of expertise and leadership to his role at Nuvem, as Chief [PR.com] https://www.pr.com/press-release/915956 Nuvem https://www.pr.com/press-release/915829 Tue, 16 Jul 2024 05:00:00 -0400 Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side [PR.com] https://www.pr.com/press-release/915829 Courage Therapeutics https://www.pr.com/press-release/914397 Sun, 23 Jun 2024 03:00:00 -0400 I Holland, has launched its new Safe Disposal &Recycling Service. This valuable service is designed to ensure the safe, secure, and environmentally responsible destruction of obsolete or worn-out tooling, enhancing both the integrity and sustainability of pharmaceutical manufacturing. Their commitment to quality and tooling care, through all stages of its lifecycle, is now extended to the end-of-life management of [PR.com] https://www.pr.com/press-release/914397 I Holland Ltd. https://www.pr.com/press-release/912966 Fri, 31 May 2024 12:08:00 -0400 Megalabs, a leading pharmaceutical company, has acquired majority interest and control of DS Laboratories (“DS Labs”), a leading dermatology company focused on science backed hair care across 50+ countries. This strategic move enhances Megalabs' position in the global dermatology market and the US. [PR.com] https://www.pr.com/press-release/912966 Megalabs https://www.pr.com/press-release/912746 Thu, 30 May 2024 03:00:00 -0400 Sosemo LLC Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List Sosemo LLC has been awarded on the Financial Times list of The Americas’ Fastest Growing Companies 2024. This prestigious award is presented by the Financial Times and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on April 4, 2024, and can be viewed on the [PR.com] https://www.pr.com/press-release/912746 Sosemo https://www.pr.com/press-release/912086 Tue, 21 May 2024 14:53:12 -0400 Suabix™ by Successful Human Factors™, is the first AI Human Factors Copilot for medical product teams, revolutionizing the future of healthcare and patient safety. Successful Human Factors™ is also offering AI integration services tailored to stakeholders needs, powered by Suabix. [PR.com] https://www.pr.com/press-release/912086 Successful Human Factors™ https://www.pr.com/press-release/912017 Sat, 18 May 2024 03:00:00 -0400 GENINVO, a leading provider of life science products and business solutions announced the launch of its new, on-demand service: DocWrightAI. GENINVO understands the various challenges in generating clinical documents. The time taken to draft clinical documents with accuracy and compliance has always been a major concern. Drafting clinical and regulatory documents involves the creation of comprehensive and accurately [PR.com] https://www.pr.com/press-release/912017 GenInvo, Inc. https://www.pr.com/press-release/911233 Tue, 07 May 2024 00:00:00 -0400 Novugen has launched Pazopanib tablets, 200mg, in the U.S. after receiving ANDA approval from USFDA on April 23, 2024. This significant milestone demonstrates Novugen's continued growth in the U.S. pharmaceutical market with a complex anticancer drug, the generic equivalent of Votrient, used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). [PR.com] https://www.pr.com/press-release/911233 Novugen https://www.pr.com/press-release/910844 Tue, 30 Apr 2024 11:13:03 -0400 AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. [PR.com] https://www.pr.com/press-release/910844 Anzu